DSIP is misread in both directions. It is not a controlled substance, and it is also not lawful to sell for human use in the United States. Those two facts sit together because they come from different statutes: the Controlled Substances Act does not reach the peptide at all, while the Federal Food, Drug, and Cosmetic Act makes the way it is offered and sold the violation.
DSIP is not a controlled substance and carries no federal possession offense, yet it remains an unapproved new drug that section 505(a) of the Federal Food, Drug, and Cosmetic Act bars from interstate commerce for human use.
No FDA-approved drug product contains delta sleep-inducing peptide as an active ingredient, for sleep or for anything else. The distinction that gets collapsed most often is between unapproved and rejected: the agency has never evaluated the peptide and found it unsafe, it has simply never been asked to evaluate it at all. That absence is the reason no safety dossier, no dosing determination, and no manufacturing standard for the substance exists anywhere in the federal record.
FDA has never approved delta sleep-inducing peptide for any indication and holds no safety dossier, no dosing determination, and no manufacturing standard for it, because the agency has never been asked to review it.
The phrase sounds like a paperwork gap. It is a legal conclusion with teeth, and the point most often missed is that the status attaches to the article as sold rather than to the chemistry in the vial. The same powder is an unapproved new drug when it ships with reconstitution and dosing guidance, and something closer to a bench reagent when it genuinely goes to a laboratory.
Unapproved new drug status attaches to how DSIP is offered and sold rather than to the molecule, and FDA determines that intended use under 21 CFR 201.128 from objective evidence including dosing guidance, promotional statements, and a seller's knowledge of how customers actually use the product.
Compounding is where most people assume a legal door exists. The architecture explains why it does not open: both exemptions turn on the ingredient, and delta sleep-inducing peptide clears no gate on either list. A prescription does not change that, because a prescription is a condition of the 503A exemption rather than a source of it.
| Requirement | Section 503A (pharmacies) | Section 503B (outsourcing facilities) |
|---|---|---|
| Bulk substance gate | USP or NF monograph, component of an approved drug, or the 503A bulks list | The 503B bulks list, the clinical need list, or FDA's drug shortage list |
| DSIP eligibility | Fails all three routes | On neither list |
| Supply conditions | FDA-registered establishment plus a valid certificate of analysis | Interim policy sorts nominations into Category 1 or Category 2 |
| Current position | Nominated but withdrawn; PCAC review set for July 24, 2026 | No pending route |
Delta sleep-inducing peptide satisfies none of the three 503A bulk drug substance routes and appears on neither the 503B bulks list nor FDA's drug shortage list, so a valid prescription for it produces a compounded unapproved new drug rather than a lawful one.
Delta sleep-inducing peptide appears nowhere in Schedules I through V of the Controlled Substances Act, and it has never been the subject of a scheduling proceeding. The trap is treating that absence as a verdict. Not being scheduled means the DEA has no interest in the peptide; it says nothing about whether selling it is lawful, because that question belongs to a different agency under a separate statute.
DSIP is unscheduled under the Controlled Substances Act and carries no DEA registration duty or federal possession offense, yet it remains unlawful to sell for human use, making it a clean example of a substance that is simultaneously unscheduled and illegal to market.
No, and it fails on two independent grounds, either of which would be sufficient on its own. Sellers reach for the supplement frame because supplements need no premarket approval, which makes the category look like an open lane right up until the definition is read.
A synthetic nine amino acid peptide with no history of use in the food supply does not meet the dietary ingredient definition in section 201(ff), so DSIP cannot be in a dietary supplement at all, which ends the analysis before safety is ever discussed.
Research use only has an actual regulatory home, and it is narrow: 21 CFR 809.10(c) defines the designation for in vitro diagnostic products in the laboratory research phase of development. Nothing in the drug provisions of the Federal Food, Drug, and Cosmetic Act creates an exemption triggered by printing a sentence on a vial. The label does carry one honest meaning, though not the one it is invoked for.
Research use only is a designation at 21 CFR 809.10(c) for in vitro diagnostic products rather than a drug exemption, and under 21 CFR 201.128 a seller's knowledge that the material is being injected converts the disclaimer from a shield into evidence of intended use.
The border is where the government's authority is broadest, because the legal standard there is deliberately low. Section 801(a) allows FDA to refuse admission to an article that appears to be an unapproved new drug, and the operative word is appears: the agency need not prove a violation, only form a reasonable belief from the article's identity and presentation.
FDA's personal importation policy lives in chapter 9-2 of the Regulatory Procedures Manual as enforcement discretion rather than a right, and its stated contours cover a serious condition with no satisfactory domestic treatment under a named physician's care, which a peptide bought online for personal enhancement matches in essentially no respect.
FDA's posture in this sector is tiered, and the tiers explain both what happens and why so little of it is visible. The widespread sense that enforcement is light is half accurate and dangerously misread: the agency's resources are finite and it prioritizes injury, sterility risk, and scale, so a quiet low-volume seller can operate for years untouched. That is prosecutorial reality rather than legal permission, and the statute contains no de minimis exception.
FDA escalation from warning letters to seizure, injunction, and criminal prosecution tracks sterility failures, patient injury, scale, and intent to defraud rather than the bare fact of a violation, so a warning letter is a starting point rather than a ceiling.
Searching the Prohibited List for the word DSIP and finding nothing tells an athlete nothing useful. Section S0, Non-Approved Substances, covers any pharmacological substance not currently approved by any governmental regulatory health authority for human therapeutic use, and the peptide's worldwide absence of approval is precisely the trigger that category was drafted around. S0 exists so the list never has to chase every new compound by name.
WADA's S0 category prohibits DSIP at all times for athletes bound by the World Anti-Doping Code without the list ever naming it, and strict liability holds an athlete responsible for whatever a sample contains, including cross-contamination from facilities that also handle prohibited compounds.
The risk here is distributed asymmetrically, and the asymmetry is the single most important thing to understand about this market. Section 301 reaches manufacture, introduction or delivery for introduction into interstate commerce, and receipt followed by delivery for pay; it does not reach possession or personal use. That gap is why the gray market feels safe from the buyer's side, and it is also where the line gets crossed without notice.
| Exposure | Buyer | Seller | Physician or clinic |
|---|---|---|---|
| Possession or personal use | No federal offense | Not applicable | Not applicable |
| Supply or distribution | Resale or splitting an order crosses into section 301 | Unapproved new drug and misbranding baseline | Outside every compounding exemption |
| Escalation | None absent distribution | Felony under 303(a)(2); wire fraud, money laundering, smuggling | Unprofessional conduct before a state board |
| Practical loss | Money gone, shipments refused, no consumer protection | Seizure, injunction, consent decree | Malpractice coverage excluded as an uninsured act |
Section 301 does not reach possession or personal use, so a buyer moves from the unaddressed side of the statute to the prosecuted side by reselling, splitting a group order, or passing a vial along at cost, and intent to profit is not required.
Educational use only. This article describes what the published scientific and clinical literature reports about DSIP. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
